Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record.

Suppression of Retinoic Acid Receptor in Non-Small-Cell Lung Cancer In Vivo: Implications for Lung Cancer Development

Open access
Xu, X.-C., Sozzi, G., Lee, J. S., Lee, J. J., Pastorino, U., Pilotti, S., Kurie, J. M., Hong, W. K., Lotan, R.·1997·JNCI Journal of the National Cancer Institute

Abstract

BACKGROUND: Retinoids, analogues of vitamin A, are required for the normal growth and differentiation of human bronchial epithelium. They are also able to reverse premalignant lesions and prevent second primary tumors in some patients with non-small-cell lung cancer (NSCLC). These effects are thought to result from modulation of cell growth, differentiation, or apoptosis (programmed cell death). When certain retinoid receptors in the cell nucleus (i.e., retinoic acid receptors [RARs] and retinoid X receptors [RXRs]), which mediate most retinoid actions, are suppressed, abnormal activity may result that could enhance cancer development. PURPOSE: This study was designed to determine whether there are abnormalities in the expression of retinoid receptors in surgical specimens from patients with NSCLC. METHODS: Transcripts of nuclear retinoid receptors were detected in formalin-fixed, paraffin-embedded specimens by use of digoxigenin-labeled riboprobes specific for RAR alpha, RAR beta, RAR gamma, RXR alpha, RXR beta, and RXR gamma for in situ hybridization to histologic specimens from 79 patients with NSCLC and as control from 17 patients with non-lung cancer. The quality and specificity of the digoxigenin-labeled probes were determined by northern blotting, and the specificity of the binding of antisense riboprobes was verified by use of sense probes as controls. RESULTS: All receptors were expressed in at least 89% of control normal bronchial tissue specimens from 17 patients without a primary lung cancer and in distant normal bronchus specimens from patients with NSCLC. RAR alpha, RXR alpha, and RXR gamma were expressed in more than 95% of the NSCLC specimens. In contrast, RAR beta, RAR gamma, and RXR beta expression was detected in only 42%, 72%, and 76% of NSCLC, respectively. CONCLUSIONS: These data suggest that the expression of RAR alpha, RXR alpha, and RXR gamma is not altered in NSCLC; however, expression of RAR beta and possibly also of RAR gamma and RXR beta is suppressed in a large percentage of patients with lung cancer. IMPLICATIONS: The loss of expression of one or more of these nuclear retinoid receptors may be associated with lung carcinogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/89.9.624

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 201

Metadata

Authors
Xu, X.-C., Sozzi, G., Lee, J. S., Lee, J. J., Pastorino, U., Pilotti, S., Kurie, J. M., Hong, W. K., & Lotan, R.
Venue
JNCI Journal of the National Cancer Institute
Published
1997-05-07
Volume
89
Issue
9
Pages
624-629
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2114209008
Cited by
201
References
0
FWCI
6.19
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Suppression of Retinoic Acid Receptor in Non-Small-Cell Lung Cancer In Vivo: Implications for Lung Cancer Development. https://app.cochat.ai/papers/10.1093/jnci/89.9.624
The paper
Xu, X.-C., Sozzi, G., Lee, J. S., Lee, J. J., Pastorino, U., Pilotti, S., Kurie, J. M., Hong, W. K., & Lotan, R. (1997). Suppression of Retinoic Acid Receptor in Non-Small-Cell Lung Cancer In Vivo: Implications for Lung Cancer Development. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/89.9.624

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.